Open AccessERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy
Author(s) -
Özer Özdemir,
Pelin Özdemir,
Alı Veral,
Hatice Uluer,
Mustafa Hikmet Özhan
Publication year - 2013
Publication title -
asian pacific journal of cancer prevention
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 75
eISSN - 2476-762X
pISSN - 1513-7368
DOI - 10.7314/apjcp.2013.14.8.4679
Subject(s) - ercc1 , medicine , lung cancer , chemotherapy , oncology , stage (stratigraphy) , immunohistochemistry , biopsy , retrospective cohort study , radiation therapy , biology , paleontology , biochemistry , nucleotide excision repair , dna repair , gene
ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its expression is indeed associated with clinical outcomes in advanced stage NSCLC patients.